In support of this notion, we found that the depletion of CD4+ T cells one day before TC-1 tumor challenge dramatically compromised the efficacy of SA-4-1BBL/E7 vaccine as 75% mice developed tumors and succumbed to death as compared with ∼20% mice in the group without depletion. The gene discussed is CD4; the disease is neoplasm.